Clofutriben Pharmacokinetics in Patients With Impaired Renal Function
Part of paid clinical trials in Orlando, Florida.
- Sponsor
- Sparrow Pharmaceuticals
- Study ID
- NCT07227922
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Moderate Renal Impairment
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 83 Years
- Healthy Volunteers
- Accepted
Interventions
- 12mg clofutriben — DRUGEach participant will receive a single oral dose of clofutriben
Study Details
This is a Phase 1, single-center, open-label, single-dose trial. Sixteen participants are planned: 8 participants with moderate renal impairment and 8 matched control participants with normal renal function.
Key Dates
- Start date
- Nov 30, 2025
- Status verified
- Nov 2025
- Primary completion
- Apr 30, 2026
- Completion
- Jul 1, 2026
Study Design
- Enrollment
- 16 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: clofutriben
Primary Outcome Measure
1. Maximum plasma concentration (Cmax) [ Time Frame: from enrollment through treatment for 6 days. ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Orlando Clinical Research Center | Orlando | Florida | 32809 |
Find similar trials in Orlando, FL
By research site